Replies to post #210395 on Biotech Values

[RockRat]

Re TRIL:

>> In the AML cohort, one patient with minimal residual disease (consisting of 0.7% abnormal blasts at baseline) obtained a complete molecular remission after 4 infusions of TTI-621. A second marrow analysis at week 8 confirmed a complete molecular remission, the patient continues to tolerate weekly infusions of TTI-621 and remains in continued remission for 15+ weeks.

This is very good news.

Obviously, a full molecular remission is good news, but this was a patient with minimal residual disease. So with that context, how important do you think it is, that is to say, how does it seem to stack up against competition in your view?

TIA & Regards, RockRat